BRAF and melanoma: For example, BRAF inhibitors have been shown to be significantly effective in improving overall survival (OS) in patients with BRAF-mutated melanoma [76] and have recently been approved for the treatment of BRAF-mutated non-small cell lung cancer (NSCLC) [77].